@theoc
The vibe I picked up after the Azer-cel acquisition is that the quickest path to FDA registration is to target 2nd/3rd line treatment after patients have failed off the major existing drugs (SOC). That’s a setting where there are no standard treatment options so, there would be no need for expensive long running Ph3 head to head trials as Vaxinia could initially slot in as 2nd/3rd line SOC, possibly with accelerated approval. That would pave the quickest path to revenue which will bring about much better terms for a licensing agreement or acquisition.
@theocThe vibe I picked up after the Azer-cel acquisition is...
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
8.2¢ |
Change
-0.003(3.53%) |
Mkt cap ! $600.2M | |||
| Open | High | Low | Value | Volume |
| 8.5¢ | 8.6¢ | 8.2¢ | $1.246M | 14.84M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 446526 | 8.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 8.3¢ | 535664 | 2 |
View Market Depth
| Last trade - 16.10pm 03/05/2024 (20 minute delay) ? |
|
|||||
|
Last
8.2¢ |
Change
-0.003 ( 2.38 %) |
||||
| Open | High | Low | Volume | ||
| 8.6¢ | 8.6¢ | 8.2¢ | 4518456 | ||
| Last updated 15.57pm 03/05/2024 ? | |||||
| IMU (ASX) Chart |